# BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

> **NCT02788513** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 611 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** BI 425809 dose 1
- **DRUG:** BI 425809 dose 2
- **DRUG:** BI 425809 dose 3
- **DRUG:** BI 425809 dose 4
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02788513
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-11
- **Primary completion:** 2019-09-12
- **Final completion:** 2019-10-11
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2020-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788513, "BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02788513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*